310 related articles for article (PubMed ID: 10638513)
1. Pneumocystis carinii pneumonia.
Schliep TC; Yarrish RL
Semin Respir Infect; 1999 Dec; 14(4):333-43. PubMed ID: 10638513
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis carinii pneumonia: a clinical review.
Wilkin A; Feinberg J
Am Fam Physician; 1999 Oct; 60(6):1699-708, 1713-4. PubMed ID: 10537385
[TBL] [Abstract][Full Text] [Related]
3. [Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment].
González-García J; Rubio García R; Antela López A; García Alcaide F
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():36-44. PubMed ID: 9859618
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis carinii: where are we now?
Watson J
J HIV Ther; 2002 Feb; 7(1):8-12. PubMed ID: 11956498
[TBL] [Abstract][Full Text] [Related]
5. Protect yourself from Pneumocystis carinii.
AIDS Alert; 1999 Jun; 14(6):suppl 1-2. PubMed ID: 11366414
[TBL] [Abstract][Full Text] [Related]
6. [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
García Vázquez E; de Górgolas Hernández M; García Delgado R; Fernández Guerrero ML
Med Clin (Barc); 1999 Jun; 113(3):89-90. PubMed ID: 10464742
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
Deresinski SC
Semin Respir Infect; 1997 Jun; 12(2):79-97. PubMed ID: 9195673
[TBL] [Abstract][Full Text] [Related]
8. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment and prophylaxis of Pneumocystis carinii pneumonia.
Warren E; George S; You J; Kazanjian P
Pharmacotherapy; 1997; 17(5):900-16. PubMed ID: 9324180
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Stoehr A; Arasteh K; Staszewski S; Brockmeyer N; Albrecht H; Mertenskötter T; Jablonowski H; Emminger C; Rockstroh JK; Baumgarten R; Bogner J; Loch T; Plettenberg A
Eur J Med Res; 1999 Apr; 4(4):131-4. PubMed ID: 10205287
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis pneumonia.
D'Avignon LC; Schofield CM; Hospenthal DR
Semin Respir Crit Care Med; 2008 Apr; 29(2):132-40. PubMed ID: 18365995
[TBL] [Abstract][Full Text] [Related]
13. [Pneumocystis carinii pneumonia in AIDS. New concepts for an old problem].
Bottaro E
Medicina (B Aires); 1999; 59(2):187-94. PubMed ID: 10413901
[TBL] [Abstract][Full Text] [Related]
14. [New aspects of epidemiology and treatment of Pneumocystis carinii infection].
Powierska-Czarny J; Gospodarek E; Czerwionka-Szaflarska M
Pol Merkur Lekarski; 2004 Nov; 17(101):534-7. PubMed ID: 15754652
[TBL] [Abstract][Full Text] [Related]
15. [Pulmonary complications in patients with AIDS].
Oka S
Kekkaku; 2002 Jan; 77(1):37-40. PubMed ID: 11855078
[TBL] [Abstract][Full Text] [Related]
16. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Jacobson MA; French M
AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
18. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997.
San-Andrés FJ; Rubio R; Castilla J; Pulido F; Palao G; de Pedro I; Costa JR; del Palacio A
Clin Infect Dis; 2003 May; 36(9):1177-85. PubMed ID: 12715314
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
